Effects of various substances on protein C (PC)—, activated recombinant human protein C (ArhPC)—, and activated plasmatic protein C (AphPC)—mediated inhibition of neutrophil chemotaxis
. | PC . | ArhPC . | AphPC . |
|---|---|---|---|
| Medium | 1 | 1 | 1 |
| PAR1 agonist (1 μM) | 0.95 ± 0.05 (n = 3) | 0.92 ± 0.07 (n = 4) | 0.92 ± 0.08 (n = 3) |
| PAR1 antibody (10 μg/mL) | 0.90 ± 0.02 (n = 3) | 1.00 ± 0.03 (n = 3) | 0.96 ± 0.03 (n = 3) |
| PAR2 agonist (100 μM) | 1.01 ± 0.01 (n = 3) | 0.90 ± 0.03 (n = 4) | 0.91 ± 0.02 (n = 4) |
| PAR2 antibody (10 μg/mL) | 1.00 ± 0.01 (n = 3) | 1.07 ± 0.04 (n = 3) | 0.98 ± 0.07 (n = 3) |
| Protein S (10 μg/mL) | 1.03 ± 0.08 (n = 3) | 1.07 ± 0.01 (n = 3) | 1.05 ± 0.04 (n = 3) |
| Hirudin (1 U/mL) | 1.07 ± 0.03 (n = 3) | 1.09 ± 0.06 (n = 4) | 0.94 ± 0.02 (n = 4) |
| Gla-antibody (1 μg/mL) | 1.33 ± 0.11 (n = 5)* | 1.38 ± 0.06 (n = 5)* | 1.25 ± 0.03 (n = 5)* |
. | PC . | ArhPC . | AphPC . |
|---|---|---|---|
| Medium | 1 | 1 | 1 |
| PAR1 agonist (1 μM) | 0.95 ± 0.05 (n = 3) | 0.92 ± 0.07 (n = 4) | 0.92 ± 0.08 (n = 3) |
| PAR1 antibody (10 μg/mL) | 0.90 ± 0.02 (n = 3) | 1.00 ± 0.03 (n = 3) | 0.96 ± 0.03 (n = 3) |
| PAR2 agonist (100 μM) | 1.01 ± 0.01 (n = 3) | 0.90 ± 0.03 (n = 4) | 0.91 ± 0.02 (n = 4) |
| PAR2 antibody (10 μg/mL) | 1.00 ± 0.01 (n = 3) | 1.07 ± 0.04 (n = 3) | 0.98 ± 0.07 (n = 3) |
| Protein S (10 μg/mL) | 1.03 ± 0.08 (n = 3) | 1.07 ± 0.01 (n = 3) | 1.05 ± 0.04 (n = 3) |
| Hirudin (1 U/mL) | 1.07 ± 0.03 (n = 3) | 1.09 ± 0.06 (n = 4) | 0.94 ± 0.02 (n = 4) |
| Gla-antibody (1 μg/mL) | 1.33 ± 0.11 (n = 5)* | 1.38 ± 0.06 (n = 5)* | 1.25 ± 0.03 (n = 5)* |
P < .01, Mann-Whitney U test versus PC, ArhPC, or AphPC incubation alone after multiple group comparison by Kruskal-Wallis test.